Literature DB >> 2914641

Effect of proctocolectomy for chronic ulcerative colitis on the natural history of primary sclerosing cholangitis.

J R Cangemi1, R H Wiesner, S J Beaver, J Ludwig, R L MacCarty, R R Dozois, A R Zinsmeister, N F LaRusso.   

Abstract

The effect of proctocolectomy on the primary sclerosing cholangitis that frequently is associated with chronic ulcerative colitis in patients with both conditions is unknown. We have studied prospectively the progression of clinical, biochemical, cholangiographic, and hepatic histologic features in 45 patients with both primary sclerosing cholangitis and chronic ulcerative colitis to compare these variables in the 20 patients who had undergone proctocolectomy with the 25 who had not. The two groups were similar initially with regard to clinical, biochemical, cholangiographic, and hepatic histologic findings. All patients were followed for a minimum of 1 yr and overall duration of follow-up was similar in both groups (4.1 vs. 3.9 yr). Clinically, new onset of hepatomegaly, splenomegaly, esophageal varices, and ascites did not differ in patients with and without proctocolectomy. Biochemically, the serial changes in bilirubin, alkaline phosphatase, aspartate aminotransferase, prothrombin time, and albumin were similar. Histologic progression on liver biopsy did not differ between groups, nor did changes on serial cholangiograms. Proctocolectomy also had no effect on survival. We conclude that proctocolectomy for chronic ulcerative colitis has no beneficial effect on the primary sclerosing cholangitis in patients with both diseases.

Entities:  

Mesh:

Year:  1989        PMID: 2914641

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  28 in total

1.  Surgical aspects of sclerosing cholangitis. Results in 178 patients.

Authors:  F M Martin; R L Rossi; F W Nugent; F J Scholz; R L Jenkins; W D Lewis; M Gagner; E Foley; J W Braasch
Journal:  Ann Surg       Date:  1990-10       Impact factor: 12.969

Review 2.  Are the inflammatory bowel diseases autoimmune disorders?

Authors:  J Snook
Journal:  Gut       Date:  1990-09       Impact factor: 23.059

Review 3.  Primary sclerosing cholangitis: updates in diagnosis and therapy.

Authors:  Piero Portincasa; Michele Vacca; Antonio Moschetta; Michele Petruzzelli; Giuseppe Palasciano; Karel J van Erpecum; Gerard P van Berge-Henegouwen
Journal:  World J Gastroenterol       Date:  2005-01-07       Impact factor: 5.742

Review 4.  Relationship of extraintestinal involvements in inflammatory bowel disease: new insights into autoimmune pathogenesis.

Authors:  K M Das
Journal:  Dig Dis Sci       Date:  1999-01       Impact factor: 3.199

5.  Patients, cells, and organelles: the intersection of science and serendipity.

Authors:  Nicholas F Larusso
Journal:  Hepatology       Date:  2011-05       Impact factor: 17.425

Review 6.  Role of colectomy in preventing recurrent primary sclerosing cholangitis in liver transplant recipients.

Authors:  Bettina M Buchholz; Panagis M Lykoudis; Reena Ravikumar; Joerg M Pollok; Giuseppe K Fusai
Journal:  World J Gastroenterol       Date:  2018-07-28       Impact factor: 5.742

Review 7.  Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis.

Authors:  A Boudewijn de Vries; Marcel Janse; Hans Blokzijl; Rinse K Weersma
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

Review 8.  The IBD and PSC Phenotypes of PSC-IBD.

Authors:  Amanda Ricciuto; Binita M Kamath; Anne M Griffiths
Journal:  Curr Gastroenterol Rep       Date:  2018-03-28

Review 9.  Primary sclerosing cholangitis, autoimmune hepatitis and overlap syndromes in inflammatory bowel disease.

Authors:  Rebecca Saich; Roger Chapman
Journal:  World J Gastroenterol       Date:  2008-01-21       Impact factor: 5.742

10.  Complications and risk factors after ileal pouch-anal anastomosis for ulcerative colitis associated with primary sclerosing cholangitis.

Authors:  A H Kartheuser; R R Dozois; R H Wiesner; N F LaRusso; D M Ilstrup; C D Schleck
Journal:  Ann Surg       Date:  1993-04       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.